Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 22895174 
Lentine B, et al. (2012) Dephosphorylation of threonine-821 of the retinoblastoma tumor suppressor protein (Rb) is required for apoptosis induced by UV and Cdk inhibition. Cell Cycle 11, 3324-30 22895174
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T5-p - Rb (human)
Orthologous residues
Rb (human): T5‑p, Rb (mouse): A5‑p, Rb (rat): A5‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Disease tissue studied:  cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical)
 Cellular systems studied:  cell lines
 Comments:  S/T to E mutations in Rb-null C33-A cells

S230-p - Rb (human)
Orthologous residues
Rb (human): S230‑p, Rb (mouse): S224‑p, Rb (rat): S223‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Disease tissue studied:  cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical)
 Cellular systems studied:  cell lines
 Comments:  S/T to E mutations in Rb-null C33-A cells

S249-p - Rb (human)
Orthologous residues
Rb (human): S249‑p, Rb (mouse): S243‑p, Rb (rat): S242‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Disease tissue studied:  cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical)
 Cellular systems studied:  cell lines
 Comments:  S/T to E mutations in Rb-null C33-A cells

T252-p - Rb (human)
Orthologous residues
Rb (human): T252‑p, Rb (mouse): T246‑p, Rb (rat): T245‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Disease tissue studied:  cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical)
 Cellular systems studied:  cell lines
 Comments:  S/T to E mutations in Rb-null C33-A cells

T356-p - Rb (human)
Orthologous residues
Rb (human): T356‑p, Rb (mouse): T350‑p, Rb (rat): T349‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Disease tissue studied:  cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical)
 Cellular systems studied:  cell lines
 Comments:  S/T to E mutations in Rb-null C33-A cells

T373-p - Rb (human)
Orthologous residues
Rb (human): T373‑p, Rb (mouse): T367‑p, Rb (rat): T366‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Disease tissue studied:  cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical)
 Cellular systems studied:  cell lines
 Comments:  S/T to E mutations in Rb-null C33-A cells

S608-p - Rb (human)
Orthologous residues
Rb (human): S608‑p, Rb (mouse): S601‑p, Rb (rat): S600‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical), MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  S/T to E mutations in Rb-null C33-A cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
roscovitine increase at 25 microM concentration

S612-p - Rb (human)
Orthologous residues
Rb (human): S612‑p, Rb (mouse): S605‑p, Rb (rat): S604‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Disease tissue studied:  cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical)
 Cellular systems studied:  cell lines
 Comments:  S/T to E mutations in Rb-null C33-A cells

S780-p - Rb (human)
Orthologous residues
Rb (human): S780‑p, Rb (mouse): S773‑p, Rb (rat): S772‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical), MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  S/T to E mutations in Rb-null C33-A cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
roscovitine increase at 25 microM concentration

S788-p - Rb (human)
Orthologous residues
Rb (human): S788‑p, Rb (mouse): S781‑p, Rb (rat): S780‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Disease tissue studied:  cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical)
 Cellular systems studied:  cell lines
 Comments:  S/T to E mutations in Rb-null C33-A cells

S795-p - Rb (human)
Orthologous residues
Rb (human): S795‑p, Rb (mouse): S788‑p, Rb (rat): S787‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Disease tissue studied:  cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical)
 Cellular systems studied:  cell lines
 Comments:  S/T to E mutations in Rb-null C33-A cells

S807-p - Rb (human)
Orthologous residues
Rb (human): S807‑p, Rb (mouse): S800‑p, Rb (rat): S799‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Disease tissue studied:  cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical)
 Cellular systems studied:  cell lines
 Comments:  S/T to E mutations in Rb-null C33-A cells

S811-p - Rb (human)
Orthologous residues
Rb (human): S811‑p, Rb (mouse): S804‑p, Rb (rat): S803‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Disease tissue studied:  cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical)
 Cellular systems studied:  cell lines
 Comments:  S/T to E mutations in Rb-null C33-A cells

T821-p - Rb (human)
Orthologous residues
Rb (human): T821‑p, Rb (mouse): T814‑p, Rb (rat): T813‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Disease tissue studied:  bone cancer, breast cancer, cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical), MCF-7 (breast cell), Saos-2 (bone cell), SKUT-1
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
roscovitine decrease at 25microM concentration
Downstream Regulation
 Effect of modification (process):  apoptosis, inhibited

T826-p - Rb (human)
Orthologous residues
Rb (human): T826‑p, Rb (mouse): T819‑p, Rb (rat): T818‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Disease tissue studied:  cervical cancer
 Relevant cell lines - cell types - tissues:  C33-A (cervical)
 Cellular systems studied:  cell lines
 Comments:  S/T to E mutations in Rb-null C33-A cells


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.